Role of pharmacogenomics in the treatment of tuberculosis: A review

Pharmacogenomics and Personalized Medicine

Volumn 5, Issue 1, 2012, Pages 89-98

  Ramachandran, Geetha ^a   Swaminathan, Soumya ^a  

^a NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

Author keywords

Antituberculous treatment; Drug metabolism; Pharmacogenomics; Polymorphism; Tuberculosis

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; AMINOSALICYLIC ACID; ETHAMBUTOL; GENOMIC DNA; HLA ANTIGEN; ISONIAZID; KANAMYCIN; MANGANESE SUPEROXIDE DISMUTASE; MITOCHONDRIAL RNA; PYRAZINAMIDE; RIBOSOME RNA; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CYTOCHROME P450 2E1; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; RIFAPENTINE;

ABCB1 GENE; CAR GENE; CLINICAL TRIAL (TOPIC); CYP2E1 GENE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; GENE; GENETIC POLYMORPHISM; GSTM1 GENE; GSTT1 GENE; HUMAN; NAT2 GENE; OTOTOXICITY; PHARMACOGENOMICS; PXR GENE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SLCO1B1 GENE; SLCO1B1B1 GENE; TOXIC HEPATITIS; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; ALLELE; ANTIBACTERIAL ACTIVITY; DRUG ACETYLATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EXCRETION; GENE DELETION; GENE MUTATION; GENOTYPE; HEREDITY; HLA DQA1 GENE; HLA DQB1 GENE; LIVER TOXICITY; LUNG TUBERCULOSIS; NAT GENE; PERSONALIZED MEDICINE; TREATMENT OUTCOME;

EID: 84866558600     PISSN: None     EISSN: 11787066     Source Type: Journal    
DOI: 10.2147/PGPM.S15454     Document Type: Review

References (72)

1. World Health Organisation. Global TB report, 2010.
2. Crofton J. Global challenge of TB. Lancet. 1994;344(8922):609.
3. Menzies D, Benedetti A, Payder A, et al. Effect of duration and intermittency of rifampin on TB treatment outcomes: a systematic review and meta-analysis. PLoS Med. 2009;6(9):e1000146.
4. Vesell ES. Pharmacokinetic perspectives gained from twin and family studies. Pharmacol Ther. 1989;41(3):535-552.
5. Kalow W, Thang BK, Endreyi L. Hypothesis: comparisons of inter and intra-individual variations can substitute for twin studies in drug research. Pharmacokinetics. 1998;8(4):283-289.
6. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286(5439):487-491.
7. Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for inter individual differences in drug response. Annu Rev Genomics Hum Genet. 2001;2:9-39.
8. McLeod HL, Evans WE. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol. 2001;41: 101-121.
9. Lehmann H, Ryan E. Familial incidence of low pseudo cholinesterase level. Lancet. 1956;271(6934):124.
10. Alving AS, Carson PE, Flanagan CL et al. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science. 1956;124(3220): 484-485.
11. Hughes HB, Biehl JP, Jones AP, Schmidt LH. Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am Rev Tuberc. 1954;70(2):266-273.
12. Evans DA, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. Br Med J. 1960;2(5197):485-491.
13. Sachidanandam R, Weissman D, Schmidt SC, et al. A map of human genome sequence variation containing 1.42million single nucleotide polymorphisms. Nature. 2001;409(6822):928-933.
14. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature. 2004;429(6990):464-468.
15. Evans WE. Pharmacogenomics: marshalling the human genome to individualise drug therapy. Gut. 2003;52 Suppl 2:210-218.
16. [No authors listed]. Pharmacogenomics. Available at: http://en.wikipedia.org/wiki/pharmacogenomics. Accessed August 7, 2012.
17. Ellard GA, Gammon PT. Pharmacokinetics of isoniazid metabolism in man. J Pharmacokinet Biopharm. 1976;4(2):83-113.
18. Raghupati Sarma G. Isoniazid metabolism in man and its therapeutic implications. Proceedings of the Symposium on Clinical Pharmacokinetics. 1978.
19. Roy PD, Majumder M, Roy B. Pharmacogenomics of anti-TB drug-related hepatotoxicity. Pharmacogenomics. 2008;9(3):311-321.
20. Weiner M, Peloquin CA, Burman W, et al. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob Agents Chemother. 2010;54(10):4192-4200.
21. Chigutsa E, Visser ME, Swart EC, et al. The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrob Agents Chemother. 2011;55(9):4122-4127.
22. Tostmann A, Boeree MJ, Aarnoutse et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gasteroenterol Hepatol. 2008;23(2):192-202.
23. Biomedical Research and Training Institute. Pharmacogenetics and drug-drug interactions in the treatment of tuberculosis - potential clinical implications in Zimbabwe. Oct 2011. Available from: http://www.brti.co.zw.
24. Cascorbi L, Roots I. Pitfalls in N-acetyl transferase 2genotyping. Pharmacogenetics. 1999;9(1):123-127.
25. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, et al. Should we use N-acetyl transferase type 2genotyping to personalize isoniazid doses? Antimicrob Agents Chemother. 2005;49(5):1733-1738.
26. Parkin DP, Vandenplas S, Botha FJ, et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med. 1997;155(5):1717-1722.
27. Kita T, Tanigawara Y, Chikazawa S, et al. N-acetyl transferase-2genotype correlated with isoniazid acetylation in Japanese tuberculous patients. Biol Pharm Bull. 2001;24(5):544-549.
28. Mitchison DA. Drug resistance in mycobacteria. Br Med Bull. 1984; 40(1):84-90.
29. Donald PR, Sirgel FA, Botha FJ, et al. The influence of human N-acetyl transferase genotype on the early bactericidal activity of isoniazid. Clin Infect Dis. 2004;39(10):1425-1430.
30. Weiner M, Burman W, Vernon A, et al. Low isoniazid concentrations and outcome of tuberculosis treatment with once weekly isoniazid and rifapentine. Am J Respir Crit Care Med. 2003;167(10):1341-1347.
31. Selkon JB, Fox W, Gangadharam PRJ, et al. Rate of inactivation of isoniazid in south Indian patients with pulmonary tuberculosis-2. Clinical implications in the treatment of pulmonary tuberculosis with isoniazid either alone or in combination with PAS. Bull World Health Organ. 1961;25:779-792.
32. [No authors listed]. Controlled comparison of oral twice-weekly and oral daily isoniazid plus PAS in newly diagnosed pulmonary tuberculosis. Br Med J. 1973;2(5857):7-11.
33. [No authors listed]. Controlled comparison of oral twice-weekly and three once weekly regimens in the initial treatment of pulmonary tuberculosis. Bull World Health Organ. 1970;43(1):143-206.
34. [No authors listed]. Controlled comparison of two fully supervised once weekly regimens in the treatment of newly diagnosed pulmonary tuberculosis. Tubercle. 1973;54(1):23-45.
35. Sarma GR, Kailasam S, Mitchison DA, et al. Studies of serial plasma isoniazid concentrations with different doses of a slow release preparation of isoniazid. Tubercle. 1975;56(4):314-323.
36. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, et al. Decreased bioavailability of rifampin and other anti-TB drugs in patients with advanced HIV disease. Antimicrob Agents Chemother. 2004;48(11): 4473-4475.
37. Ramachandran G, Hemanth Kumar AK, Rajasekaran S, et al. Acetylator status influences bioavailability of isoniazid in patients with advanced HIV disease. SAARC J Tuberc Lung Dis HIV/AIDS. 2005;II(2):9-12.
38. Gurumurthy P, Raghupati Sarma G, Jayasankar K, et al. Single-dose pharmacokinetics of isoniazid and rifampicin in patients with chronic renal failure. Ind J Tub. 1992;39:221-228.
39. Donald PR, Parkin DP, Seifart HI, et al. The influence of dose and N-acetyl transferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. Pharmacokinet Dispos. 2007;63(7):633-639.
40. Wilkins JJ, Langdon G, McIlleron H, et al. Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients. Br J Clin Pharmacol. 2011;72(1): 51-62.
41. Jeena PM, Bishai WR, Pasipanodya JG, Gumbo T. In silico children and the glass mouse model; clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis. Antimicrob Agents Chemother. 2011;55(2):539-545.
42. McIlleron H, Willemse M, Werely CJ, et al. Isoniazid plasma concentrations in a cohort of south African children with tuberculosis: implications for international pediatrics dosing guidelines. Clin Infect Dis. 2009;48(11):1547-1553.
43. Cranswick N, Mulholland K. Isoniazid treatment of children: can genetics help guide treatment? Arch Dis Child. 2005;90(6):551-553.
44. Schaaf HS, Parkin DP, Seifart HI, et al. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch Dis Child. 2005; 90(6):614-618.
45. Devadatta S, Gangadharam PRJ, Andrews RH, et al. Peripheral neuritis due to isoniazid. Bull World Health Organ. 1960;23:587-598.
46. No authors listed. The prevention and treatment of isoniazid toxicity in the therapy of pulmonary tuberculosis 2. An assessment of the prophylactic effect of pyridoxine in low dosage. Bull World Health Organ. 1963;29: 457-481.
47. Mitchell JR, Zimmerman HJ, Ishak KG, et al. Isoniazid liver injury: clinical spectrum, pathology and probable pathogenesis. Ann Intern Med. 1976;84(2):181-192.
48. Ellard GA. Slow release preparation of isoniazid: pharmacological aspects. Bull Int Union Tuberc. 1976;51(1):143-154.
49. Sarma GR, Immanuel C, Kailasam S, et al. Rifampin induced release of hydrazine from isoniazid: a possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin. Am Rev Respir Dis. 1986;133(6):1072-1075.
50. Ohno M, Yamaguchi I, Yamamoto I, et al. Slow N-acetyltransferase 2genotype affects the incidence of isoniazid and rifampicin induced hepatotoxicity. Int J Tuberc Lung Dis. 2000;4(3):256-261.
51. Huang YS, Chern HD, Su WJ, et al. Polymorphisms of N-acetyl transferase 2gene as susceptibility risk factors for anti-tuberculosis drug induced hepatitis. Hepatology. 2002;35(4):883-889.
52. Cho HJ, Koh WJ, Ryu YJ, et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with anti tuberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb). 2007;87(6):551-556.
53. Mahmoud BL, Ghozzi H, Kamoun A, et al. Polymorphism of the N-acetyltransferase 2gene as a susceptibility risk factor for anti-tuberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis. Pathol Biol (Paris). Aug 2011. [Epub ahead of print.]
54. Hiratsuka MY, Kushikawa Y, Takekuma M, et al. Genotyping of the N-acetyltransferase polymorphism in the prediction of adverse reactions to isoniazid in Japanese patients. Drug Metab Pharmacokinet. 2002; 17(4):357-362.
55. Wang PY, Xie SY, Hao Q, Xiang BF. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: meta-analysis. Int J Tuberc Lung Dis. 2012;16(5):589-595.
56. Leiro-Fernandez V, Valverde D, Vazques-Gallardo R, et al. N-acetyl transferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians. Int J Tuberc Lung Dis. 2011;15(10): 1403-1408.
57. Roy B, Chowdhury A, Kundu S, et al. Increased risk of anti-tuberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 null mutation. J Gastroenterol Hepatol. 2001;16(9):1033-1037.
58. Vuilleumier N, Rossier MF, Chiappe A, et al. CYP2E1genotype and isoniazid induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol. 2006;62(6):423-429.
59. Nelson SD, Mitchell JR, Timbrell JA, Snodgrass WR, Corcoran GB 3rd. Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat. Science. 1976;193(4256):901-903.
60. Yue J, Peng RX, Yang J, Kong R, Liu J. CYP2E1 mediated isoniazid induced hepatotoxicity in rats. Acta Pharmacol Sin. 2004;25(5): 699-704.
61. Huang YS, Chern HD, Su WJ, et al. Cytochrome P450 2 E1genotype and the susceptibility to anti tuberculosis drug induced hepatitis. Hepatology. 2003;37(4):924-930.
62. Lee SW, Chung LS, Huang HH, et al. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuberc Lung Dis. 2010; 14(5):622-626.
63. Roy B, Ghosh SK, Sutradhar D, et al. Predisposition of anti-tuberculosis drug induced hepatotoxicity by cytochrome P450 2E1genotype and haplotype in pediatrics patients. J Gastroenterol Hepatol. 2006;21(4):781-786.
64. Strange RC, Jones PW, Fryer AA. Glutathione S-transferase: genetics and role in toxicology. Toxicol Lett. 2000;112-113:357-363.
65. Simon T, Becquemont L, Mary-Krause M, et al. Combined glutathione S-transferase M1 and T1genetic polymorphism and tacrine hepatotoxicity. Clin Pharmacol Ther. 2000;67(4):432-437.
66. Huang YS, Su WJ, Huang YH, et al. Genetic polymorphisms of managanese superoxide dismutase, NAD(P)H: quinone oxidoreductase, glutathione S-transferase M1 and T1 and the susceptibility to drug induced liver injury. J Hepatol. 2007;47(1):128-134.
67. Sharma SK, Balamurugan A, Saha PK, et al. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during anti-tuberculosis treatment. Am J Respir Crit Care Med. 2002;166(7):916-919.
68. Grosset JH, Rosenthal IM, Zhang M, et al. Dose ranging comparison of rifampin and rifapentine in combination with isoniazid and pyrazinamide in the mouse model of tuberculosis. Abstract A-1825 presented at the 46th Annual Meeting of American Society for Microbiology and Infectious Diseases Society of America, October 25-28, 2008, Washington DC.
69. Jayaram R, Gaonkar S, Kaur P, et al. Pharmacokinetics and pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother. 2003;47(7):2118-2124.
70. Ji B, Truffot Pernot C, Lacroix C, et al. Effectiveness of rifampin, rifabutin and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis. 1993;148(6 Pt 1):1541-1546.
71. Zhao H, Li R, Wang Q, et al. Maternally inherited aminoglycoside-induced and nonsyndromic deafness is associated with the novel C1494T mutation in the mitochondrial 12S rRNA gene in a large Chinese family. Am J Hum Genet. 2004;74(1):139-152.
72. Yamada S, Tang M, Richardson K, et al. Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics. 2009;10(9):1433-1445.